An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
Ciudad de Buenos Aires, Buenos Aires 1025, Argentina
Haerbin, Heilongjiang 150081, China
Kashiwa-shi, Chiba 2778577, Japan
Kurume-shi, Fukuoka 8300011, Japan
Ota-shi, Gunma 3730828, Japan
Akashi-shi, Hyōgo 6738558, Japan
Kurashiki-shi, Okayama-ken 7100052, Japan
Hirakata-shi, Osaka 5731191, Japan
Osakasayama-shi, Osaka 5890014, Japan
Takatsuki-shi, Osaka 5698686, Japan
Hidaka-shi, Saitama 3501298, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Sunto-gun, Shizuoka 4118777, Japan
Chuo-ku, Tokyo 1040045, Japan
Koto-ku, Tokyo 1358550, Japan
Shinjuku-ku, Tokyo 1600023, Japan
Ube-shi, Yamaguchi 7550241, Japan
Df, Mexico City 06720, Mexico
Romania, 400015, Romania
Saxonwold, Johannesburg, Gauteng 2196, South Africa
Gangnam-gu, 06351, South Korea
Cambridgeshire, CB2 2QQ, United Kingdom
Surrey, SM2 5PT, United Kingdom